Date: 27 August 2019

Time: 4.00 – 6.30pm
Venue: Marina Bay Sands Expo & Convention Centre, Level 3, Cassia 3311
(By Invitation Only)

Synopsis

Is the endgame of innovation a product benefitting all stakeholders along the value chain? If so, can there ever be a confluence of private and public interests in R&D?

The process leading to a successful commercialisation becomes highly complex when multiple parties are involved, each desiring to achieve their particular goals. Commercial development, government accountability, and academic research have traditionally been seen as incongruous. They reflect the tussle between a company’s bottom line versus government’s drive for transparency and accessibility underpinned by an academic pursuit for knowledge rather than profits. How might companies and technology transfer offices balance these disparate aspirations?

The 8th COP is privileged to have Dr. Tony Raven, Chief Executive, Cambridge Enterprise and Dr. Yaron Daniely, CEO and President Yissum Research Development Company, Co-Chairman, Israel Tech Transfer Network to share with participants the secret behind the success of their trades. Issues relating to partnerships and licensor-licensee arrangements will be addressed, as they have extensive experience bringing technologies through to successful commercialisation involving multiple parties.

Cambridge Enterprise is the commercialisation arm of the University of Cambridge, which was ranked second most innovative university in the UK and 18th globally (Reuters World's Most Innovative Universities Ranking 2018). It raised more than £14.1 million from its excellence in innovation commercialisation in 2018.

Yissum, the technology transfer company of the Hebrew University of Jerusalem, is Israel's largest technology transfer office with over 10,000 patents registered. It has licensed more than 900 technologies and established over 135 spin-off companies, including Mobileye and BriefCam.

Join us as we hear from some of the best in the field of technology transfer, their innovation journeys and commercialisation successes.